Aditum Bio

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large. The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work. We Partner We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest. We Build We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed. We Industrialize We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science. Our People We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value. We launch new companies and support strategic investments Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic. We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster. We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future. Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them

Claris Ventures SGR is a venture capital firm based in Italy, founded in 2019. Its first fund under management, Claris Biotech I, is focused on early stage investments in high potential biopharma companies arisen from the Italian R&D ecosystem – both local and international We identify and support innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. We aim at the highest impact possible on highly unmet patients need, building value around strong science. Our pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy. Claris Ventures is authorized by Banca d’Italia (Albo SGR – Sezione Gestori di FIA – n. 176) and it is a member of the AIFI (Italian Private Equity and Venture Capital Association). Strategy Claris Ventures is the first VC firm in Italy with focus on biopharma projects ready to start clinical studies in 12-24 months. Our team provides resources, capabilities and connections to complete preclinical studies and run first in human trials. We are particularly interested in oncology, immunology, rare diseases and other therapeutic areas with limited treatment opportunities. Claris Ventures allows scientific founders to focus on science and development, while supporting project management, finance and strategic development.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Curie.Bio is a unique combination of two businesses: we act as both your drug discovery copilot & seed investor. We have some of the world’s best drug hunters, drug makers, experts, and vendors supporting our founders to increase their chances of developing successful medicines. By support, we don’t mean just a couple of hours a month. We are in the trenches with you on a day-to-day basis operating as fully integrated members of your team. We help you choose therapeutic targets, set milestones based on investor feedback, and design experimental plans. We interview and select drug discovery vendors to enable you to hit those milestones. We help identify what expertise needs to be brought in to support your key programs and then get you the right experts. We evaluate incremental data readouts with you to help determine which experiments need to be adjusted from the initial plan. We do real work. When you’re ready for your Series A, we work with you end-to-end on your data room, deck, and pitch. We make investor intros and coach you on how to run an excellent fundraising process to optimize the quality of your round. Curie.Bio’s model gives you a higher chance of success & reduces future dilution. How? By working with us, you make significant progress on your lead program(s) while being extremely capital efficient. We provide real help designing and executing your seed plan, including navigating the bumps, twists, and turns all along the way. This progress leads to better terms when raising a Series A & Series B. Investors now have a clear line of sight to getting your lead program(s) into the clinic. Post Curie.Bio’s seed, founders are positioned to raise significant capital to advance their programs without giving up as much future equity in their company. Simply put: better planning and more progress at the seed means a significantly higher chance of a future where you retain control, upside, and agency over your own company. Why us?Our team has brought over 60 drugs into the clinic with 12 approvals. Our team has founded biotech companies with more than $30 billion in enterprise value. We aim to bring our decades of experience to founders across the globe and have raised over $500m to make our vision a reality. We started with a problem statement: you can’t start a therapeutics company in your garage. Drug discovery is an incredibly complex process with multiple points of failure, particularly in the earliest stages of building a new company. We’re launching with a big idea: if we can help founders avoid mistakes, ensure they have the right data, plan & story, all while retaining the incentive to build their own company, we could in essence, free the founders. We believe the single greatest unlock of innovation in biotech over the next decade will come from creating more founders – more risk takers – more scientists with phenomenal ideas who have the support they need to start their own company.